AMTI News and Press, Applied Molecular Transport Inc. From 05/09/22

Applied Molecular Transport press release (NASDAQ:AMTI): Q1 GAAP EPS of -$1.10 misses by $0.35. As of March 31, 2022, cash and cash equivalents were $126.5 million. The Company believes its cash and cash equivalents will be sufficient to allow the Company to fund its current operating plan fo...

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis...

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the ...

AMTI is developing a medicine for pouchitis. The company is undercovered and maybe undervalued. Its drug delivery platform is its key asset. For further details see: Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

Applied Molecular Transport (NASDAQ:AMTI) reported data from a phase 2 trial of AMT-101 to treat patients with chronic pouchitis. Pouchitis is an inflammation that occurs in the lining of a pouch which is created during surgery to treat ulcerative colitis (UC). In certain patients with UC, pa...

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD) –  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile ȁ...

- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results f...

Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company’s proprietary biologic product candidates to cross intestinal epithelial barrier Deep characterization of natural molecular ...

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical ex...

Gainers: Qurate Retail (QRTEA) +19%. lululemon athletica  (LULU) +7%. Cue Health  (HLTH) +7%. Spero Therapeutics (SPRO) +6%. Applied Molecular Transport  (AMTI) +6%. Losers: Stronghold Digital Mining (SDIG) -26%. Braze (BRZE) -11%. Global-E Online ...